Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Effects of Nimodipine on the Pharmacokinetics of Warfarin in Rats: A Possible Role of P-glycoprotein and CYP3A4 Inhibition by Nimodipine

와파린의 약물동태학에 니모디핀의 영향

  • Received : 2013.08.01
  • Accepted : 2013.09.06
  • Published : 2013.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The aim of this study was to investigate the effect of nimodipine on the pharmacokinetics of warfarin after oral and intravenous administration of warfarin in rats. Methods: Warfarin was administered orally (0.2 mg/kg) or intravenously (0.05 mg/kg) without or with oral administration of nimodipine (0.5 or 2 mg/kg) in rats. The effect of nimodipine on the P-glycoprotein as well as cytochrome P450 (CYP) 3A4 activity was also evaluated. Results: Nimodipine inhibited CYP3A4 enzyme activity with 50% inhibition concentration ($IC_{50}$) of $10.2{\mu}M$. Compared to those animals in the oral control group (warfarin without nimodipine), the area under the plasma concentration-time curve (AUC) of warfarin was significantly greater (0.5 mg/kg, P<0.05; 2 mg/kg, P<0.01) by 31.3-57.6%, and the peak plasma concentration ($C_{max}$) was significantly higher (2 mg/kg, P<0.05) by 29.4% after oral administration of warfarin with nimodipine, respectively. Consequently, the relative bioavailability of warfarin increased by 1.31- to 1.58-fold and the absolute bioavailability of warfarin with nimodipine was significantly greater by 64.1-76.9% compared to that in the control group (48.7%). In contrast, nimodipine had no effect on any pharmacokinetic parameters of warfarin given intravenously. Conclusion: Therefore, the enhanced oral bioavailability of warfarin may be due to inhibition of CYP 3A4-mediated metabolism rather than P-glycoprotein-mediated efflux by nimodipine.

Keywords

References

  1. Kazda S, Garthoff B, Krause HP, et al., Cerebrovascular effects of the calcium antagonistic dihydropyridine derivative nimodipine in animal experiments. Arzneimittelforschung 1982; 32: 331-338.
  2. Epstein, M, Loutzenhister, RD. Effects of calcium antagonists on renal hemodynamics. Am J Kidney Dis 1990; 16: 10-14.
  3. Kim TW, Choi JS. Pharmacokinetic interaction between ticlopidine and nimodipine in rats. Kor J Clin pharm 2010; 20: 254-259.
  4. Maruhn D, Siefert HM, Weber H, et al., Pharmacokinetics of nimodipine. communication: absorption, concentration in plasma and excretion after single administration of nimodipine in rat, dog and monkey. Arzneimittelforschung 1985; 5: 1781-1786.
  5. Suwelack D, Weber H, Maruhn D. Pharmacokinetics of nimodipine, communication: absorption, concentration in plasma and excretion after single administration of nimodipine in rat, dog and monkey. Arzneimittelforschung 1985; 35: 1787-1794.
  6. Saeki T, Ueda K, Tanigawara Y, et al., P-glycoproteinmediated transcellular transport of MDR-reversing agents. FEBS Lett 1993; 324 : 99-102. https://doi.org/10.1016/0014-5793(93)81540-G
  7. Wacher VH, Silverman JA, Zhang Y, et al., Role of Pglycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics. J Pharm Sci 1998; 87: 1322-1330. https://doi.org/10.1021/js980082d
  8. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993; 62: 385-427. https://doi.org/10.1146/annurev.bi.62.070193.002125
  9. Gan LL, Moseley MA, Khosla B, et al., CYP3A-Like cytochrome P450-mediated metabolism and polarized efflux of cyclosporin A in Caco-2 cells: interaction between the two biochemical barriers to intestinal transport. Drug Metab Dispos 1996; 24: 344-349.
  10. Ito K, Kusuhara H, Sugiyama Y. Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption theoretical approach. Pharm Res 1999; 16: 225-231. https://doi.org/10.1023/A:1018872207437
  11. Watkins PB. The barrier function of CYP3A4 and Pglycoprotein in the small bowel. Adv. Pharm. Drug Deliv Rev 1996; 27: 161-170.
  12. Hirsh J, Dalen JE, Anderson DR, et al., Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998; 114: 445-469. https://doi.org/10.1378/chest.114.5_Supplement.445S
  13. Wallin R, Sane DC, Hutson SM. Vitamin K 2,3-epoxide reductase and the vitamin K-dependent gamma-carboxylation system. Thromb Res 2002; 108: 221-226. https://doi.org/10.1016/S0049-3848(03)00060-4
  14. Mungall DR. Population pharmacokinetics of racemic warfarin in adult patients. J Pharmacokinet Biopharm 1985; 13: 213-227. https://doi.org/10.1007/BF01065653
  15. Holford NHG. Clinical pharmacokinetics and pharmacodynamics of warfarin: understanding the dose-effect relationship. Clin Pharmacokinet 1986; 11: 483-504. https://doi.org/10.2165/00003088-198611060-00005
  16. Scordo MG, Pengo V, Spina E, et al., Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 2002; 72: 702-710. https://doi.org/10.1067/mcp.2002.129321
  17. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73: 67-74. https://doi.org/10.1016/S0163-7258(96)00140-4
  18. Zhu M, Chan KW, Ng LS, et al., Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. J Pharm Pharmacol 1999; 51: 175-180. https://doi.org/10.1211/0022357991772105
  19. Crespi CL, Miller VP, Penman BW. Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450. Ana Biochem 1997; 248: 188-190. https://doi.org/10.1006/abio.1997.2145
  20. Han CY, Cho KB, Choi HS, et al., Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells. Carcinogenesis 2008; 29: 1837-1844. https://doi.org/10.1093/carcin/bgn092
  21. Cummins CL, Jacobsen W, Bene, LZ. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002; 300: 1036-1045. https://doi.org/10.1124/jpet.300.3.1036
  22. Benet LZ, Cummins CL, Wu CY. Transporter-enzyme interactions: implications for predicting drug-drug interactions from in vitro data. Curr Drug Metab 2003; 4: 393-398. https://doi.org/10.2174/1389200033489389
  23. Darvari R, Boroujerdi M. Concentration dependency of modulatory effect of amlodipine on P-glycoprotein efflux activity of doxorubicin - a comparison with tamoxifen. J Pharm Pharmacol 2004; 56: 985-991. https://doi.org/10.1211/0022357043941
  24. Wacher VJ, Salphati L, Benet LZ. Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 2001; 46: 89-102. https://doi.org/10.1016/S0169-409X(00)00126-5
  25. Choi DH, Kim HY, Choi JS. Effect of naringin on the bioavailability of nimodipine in rabbits. Kor J Clin pharm 2008; 18: 261-267.
  26. Choi DH, Piao YJ, Choi EJ, et al., Effects of amlodipine on the pharmacokinetics of warfarin after oral and intravenous administration of warfarin in rats. Biomol Ther 2011; 19: 493-497. https://doi.org/10.4062/biomolther.2011.19.4.493
  27. Choi JS, Piao YJ, Han HK. Phatmacokinetics interaction between fluvastatin and diltiazem in rats. Biopharm Drug Dispos 2006; 27: 437-441. https://doi.org/10.1002/bdd.521
  28. Yusa K, Tsuruo T. Reversal mechanism of multidrug resistance by verapamil: direct binding of verapamil to Pglycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res 1989; 49: 5002-5006.
  29. Harmsze AM, Robijns K, van Werkum JW, et al., The use of amlodipine, but not of P-glycoprotein inhibiting calcium channel blockers is associated with clopidogrel poor-response. Thromb Haemos 2010; 103: 920-925. https://doi.org/10.1160/TH09-08-0516
  30. Abernethy DR, Kaminsky LS, Dickinson TH. Selective inhibition of warfarin metabolism by diltiazem in humans. J Pharmacol Exp Ther 1991; 257: 411-415.
  31. Stoysich AM, Lucas BD, Mohiuddin SM, et al., Further elucidation of pharmacokinetic interaction between diltiazem and warfarin. Int J Clin Pharmacol Ther 1996; 34: 56-60.